IRVINE, Calif.--(BUSINESS WIRE)--Jan. 21, 2016--
Masimo
(NASDAQ: MASI) announced today that in a new study that compared
acoustic respiration rate (RRa®) from Masimo’s rainbow® Acoustic
Monitoring (RAMTM) to respiration rate from conventional
capnography, researchers concluded that RAM was useful for monitoring
dental patients under intravenous anesthesia.1
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20160121005486/en/
rainbow Acoustic Monitoring (RAM) from Masimo. (Photo: Business Wire)
The Anesthesia Patient Safety Foundation (APSF) and The Joint Commission
recommend continuous oxygenation and ventilation monitoring in all
patients receiving opioid-based pain medications.² RAM noninvasively and
continuously measures respiration rate using an innovative adhesive
sensor with an integrated acoustic transducer that is easily and
comfortably applied to the patient’s neck.
The study, published in the Journal of Clinical Monitoring and
Computing by Dr. Kentaro Ouchi and colleagues from Japan, compared
the respiration rate measurements from RAM and capnography (Psychorich
IS nasal cannula and BP-608 Omron Colin monitor) in non-intubated
patients with dental anxiety undergoing dental treatment. A total of
1953 data points of respiratory rate were taken from the start to the
end of anesthesia. Over the entire observation period, the results
showed a significantly higher detection of respiratory rate by RAM (1884
points, 96.5%) than by capnography (1682 points, 86.1%) P < 0.0001. When
comparing respiration rate from RAM and capnography during the
induction, intraoperative, and emergence periods, the 95% limits of
agreement (LOA) were -7.4 to 6.7 , -5.4 to 7.0, -3.9 to 5.3,
respectively. The researchers commented that this study was only a
comparison between two devices, since neither method could be considered
a “corrective control,” or gold-standard reference.
The authors concluded, “In comparison between capnography using a nasal
cannula for continuous monitoring for the respiratory rate, the acoustic
method is useful during intravenous general anesthesia in unintubated
spontaneously breathing patients undergoing dental procedures.” The
authors note that the acoustic method might not accurately detect
respiratory rate in cases in which a dental air turbine is used.
For more information on the RAM Acoustic Respiratory Rate Monitoring
System, go to www.masimo.com.
@MasimoInnovates
| #Masimo
References
1 Ouchi (et al.), Acoustic Method Respiratory Rate Monitoring is Useful
in Patients Under Intravenous Anesthesia. J Clin Monit Comput
2016; published online.
2 Stoelting, RK et al. APSF newsletter. 2011. www.apsf.org.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. The benefits of Masimo SET® have
been proven in more than 100 independent and objective studies and it is
estimated to be used on more than 100 million patients in leading
hospitals and other healthcare settings around the world. In 2005,
Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total hemoglobin
(SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and more recently, Pleth Variability Index
(PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate,
and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive
open architecture patient monitoring and connectivity platform designed
to speed the pace of innovation and reduce the cost of care. Masimo is
also taking an active leadership role in mHealth with products such as
the Radius-7™ wearable patient monitor and the MightySat™ fingertip
pulse oximeter. Additional information about Masimo and its products may
be found at www.masimo.com.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results or studies;
risks related to our belief that Masimo's unique noninvasive measurement
technologies, including Masimo’s rainbow® Acoustic Monitoring (RAMTM)
contribute to positive clinical outcomes and patient safety; risks
related to our belief that Masimo noninvasive medical breakthroughs
provide cost-effective solutions with comparable accuracy and unique
advantages, including: immediate and continuous results that enable
earlier treatment without causing invasive trauma in all patients and in
every clinical situation, including the dental setting; as well as other
factors discussed in the "Risk Factors" section of our most recent
reports filed with the Securities and Exchange Commission ("SEC"),
which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160121005486/en/
Source: Masimo
Masimo
Irene Paigah, 858-859-7001
irenep@masimo.com